Recent Updates
Recently added Catalysts
NRXP Positive Sentiment

Jane King, NASDAQ MarketSite interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals

Thursday, November 30, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: In an interview with Jane King at the NASDAQ MarketSite, Dr. Jonathan C. Javitt discussed NRx-101, the first investigational drug undergoing FDA trials specifically for suicidal bipolar depression. The conversation highlighted the significance of this drug in addressing a critical mental health issue and showcased Dr. Javitt's role in advancing treatment options through NRx Pharmaceuticals.
Price reaction · baseline $3.375 (2023-11-30T20:17:00.000Z) · hit during market hours · clean, no other NRXP news in the window
day 0 close · peak
+1.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Interview highlights NRx-101's potential in treating suicidal bipolar depression.
  • Dr. Javitt's leadership at NRx Pharmaceuticals showcases innovation in mental health.
  • FDA trials signify a critical step for new treatment options.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+167%
120-day peak, hindsight
Typical move
4.3%
average across 2 past catalysts
Cash runway
~12 mo
Low dilution risk
Lead asset
NRX-101
Phase 2 · Bipolar Depression

Full Press Release Details

Veteran broadcaster Jane King from the NASDAQ MarketSite in Times Square interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing NRx-101 – the first investigational drug in FDA trials for suicidal bipolar depression.

Frequently Asked Questions

What is NRx-101?

NRx-101 is the first investigational drug in FDA trials for suicidal bipolar depression.

Who is Dr. Jonathan C. Javitt?

Dr. Jonathan C. Javitt is the Chief Scientist, Director, and Founder of NRx Pharmaceuticals.

What was discussed in the interview?

The interview focused on NRx-101 and its significance in treating suicidal bipolar depression.

Where was the interview held?

The interview took place at the NASDAQ MarketSite in Times Square.

ShareAdd on Google
Tags: NRXP Viatris Investor Conferences Healthcare NRx Pharmaceuticals Jonathan Javitt bipolar depression FDA trials mental health
Last updated: Nov 30, 2023

Biotech snapshot

Cash runway
$27M liquidity · $2M/mo burn
~12 mo
Low dilution risk
Lead asset
NRX-101Phase 2
Bipolar Depression →

Catalyst track record

+167%
best trade around NRXP's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for NRXP.

See every catalyst's timing & PoA →